To compare outcomes of intravitreal therapy from an observational study cohort with those of participants receiving treatment in the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab ( MARINA ) for the treatment of neovascular age-related macular degeneration ( wet AMD ) .